NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a phyto-medical company, announced today that the Company’s CEO Dean Petkanas will be presenting at the 2018 Cannabinoids in Medicine Summit in Los Angeles on Saturday, April 28. Petkanas will be speaking on “Industry Advancements and New Frontiers – New Research Findings, Novel Drugs and Unique Delivery Systems” at 5:15pm PT.

The 2018 Cannabinoids in Medicine Summit brings together physicians, registered nurses and pharmacists engaged in the care of patients with various chronic diseases, allowing participants to learn from an elite group of experts about newer cannabinoid research and evidenced-based reviews examining the efficacy and safety of cannabinoids in critical therapeutic areas.

“At Kannalife we are always pleased to be called to participate at industry symposiums and conferences that focus on Cannabinoid therapeutics in the clinical setting.” Petkanas said “The Cannabinoid based therapeutics market is moving at a rapid pace, as seen by the recent 13-0 vote from the FDA’s advisory panel in favor of market approval for GW Pharmaceutical’s epilepsy drug EpidiolexTM. As for Kannalife, we are seeing great progress in the potential benefits of our own proprietary cannabidiol derived compound KLS-13019 in the treatment of disorders like Chemotherapy Induced Neuropathic Pain (CINP) and chronic diseases like Hepatic Enchephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE).”

About Kannalife Sciences
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.


Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070